Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Butantan vs Sanofi Trivalent Seasonal Influenza Vaccine
NCT03777163Phase 4Completed
- Sponsor
- Instituto Butantan
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Butantan Influenza Trivalent, Fragmented and Inactivated in influenza (2 arms), sponsored by Instituto Butantan. Primary endpoints: Geometric Mean Titers of Hemaglutination Inhibition at 21 days, Adverse events occurring over the immediate 30-minute post vaccination and 4 more. Started Apr 2019; status: completed.
02
Drugs
Butantan Influenza Trivalent, Fragmented and Inactivated
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03777163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777163.